MX2021006527A - Compuesto macrociclico y su uso. - Google Patents

Compuesto macrociclico y su uso.

Info

Publication number
MX2021006527A
MX2021006527A MX2021006527A MX2021006527A MX2021006527A MX 2021006527 A MX2021006527 A MX 2021006527A MX 2021006527 A MX2021006527 A MX 2021006527A MX 2021006527 A MX2021006527 A MX 2021006527A MX 2021006527 A MX2021006527 A MX 2021006527A
Authority
MX
Mexico
Prior art keywords
disease
kidney
mitochondrial
inflammatory
formula
Prior art date
Application number
MX2021006527A
Other languages
English (en)
Inventor
Ayumu Niida
Shigemitsu Matsumoto
Naoyoshi Noguchi
Toshitake Kobayashi
Tsuyoshi Maekawa
Satoshi Sasaki
Ryoma Hara
Minoru Ikoma
Hideto Fukushi
Original Assignee
Scohia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scohia Pharma Inc filed Critical Scohia Pharma Inc
Publication of MX2021006527A publication Critical patent/MX2021006527A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto representado por la fórmula (I): (ver Fórmula) donde cada símbolo es como se lo define en la presente, o una sal de éste, que presenta actividad de activación sobre NRF2, del cual se espera que sea útil como agente preventivo o terapéutico para enfermedades asociadas al estrés oxidativo, particularmente, enfermedades hepáticas (por ejemplo, esteatohepatitis no alcohólica (ENA)), enfermedades cardiovasculares (por ejemplo, insuficiencia cardíaca o hipertensión arterial pulmonar), enfermedades pulmonares (por ejemplo, enfermedad pulmonar obstructiva crónica (EPOC)), enfermedades renales (por ejemplo, enfermedad renal crónica (ERC) o lesión renal aguda (LRA)), enfermedades en el sistema nervioso central (por ejemplo, enfermedad de Parkinson), enfermedades mitocondriales (por ejemplo, ataxia motora de Friedreich o miopatía mitocondrial), enfermedades inflamatorias (por ejemplo, esclerosis múltiple (EM) o enfermedad inflamatoria intestinal (EII)), enfermedades en las células falciformes, cánceres o similares.
MX2021006527A 2018-12-05 2019-12-04 Compuesto macrociclico y su uso. MX2021006527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018228234 2018-12-05
PCT/JP2019/048593 WO2020116660A1 (en) 2018-12-05 2019-12-04 Macrocyclic compound and use thereof

Publications (1)

Publication Number Publication Date
MX2021006527A true MX2021006527A (es) 2021-07-21

Family

ID=70975488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006527A MX2021006527A (es) 2018-12-05 2019-12-04 Compuesto macrociclico y su uso.

Country Status (17)

Country Link
US (1) US11518763B2 (es)
EP (1) EP3890738A4 (es)
JP (1) JP2022510736A (es)
KR (1) KR20210099622A (es)
CN (1) CN113164468A (es)
AR (1) AR117251A1 (es)
AU (1) AU2019391942B2 (es)
BR (1) BR112021010704A2 (es)
CA (1) CA3121952A1 (es)
CL (1) CL2021001451A1 (es)
CO (1) CO2021007304A2 (es)
MX (1) MX2021006527A (es)
PH (1) PH12021551262A1 (es)
SG (1) SG11202105125XA (es)
TW (1) TWI820266B (es)
UA (1) UA127872C2 (es)
WO (1) WO2020116660A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4364804A2 (en) 2018-08-20 2024-05-08 Janssen Pharmaceutica NV Inhibitors of keap1-nrf2 protein-protein interaction
KR20230104126A (ko) * 2020-09-14 2023-07-07 사노피 적혈구 질환 및 염증성 질병의 치료를 위한 테트라하이드로이소퀴놀린 유도체

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029393T2 (en) 2010-08-31 2017-03-28 Bionure Farma S L Neurotrophin receptor agonists and their use as medicaments
CN105339358B (zh) 2013-06-21 2019-06-04 卡尔约药物治疗公司 核转运调节剂及其用途
EP3083614B1 (en) * 2013-12-18 2020-01-15 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators
MA52309A (fr) 2015-06-15 2021-02-24 Astex Therapeutics Ltd Régulateurs de nrf2
CA2988373A1 (en) 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
EP3766878B1 (en) 2015-06-15 2022-03-16 GlaxoSmithKline Intellectual Property Development Limited Nrf2 regulators
US10201531B2 (en) 2015-08-12 2019-02-12 Mochida Pharmaceutical Co., Ltd. Indazolyl-oxo-isothiazole compounds
WO2017060854A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as nrf2 regulators
WO2017060855A1 (en) 2015-10-06 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Arylcyclohexyl pyrazoles as nrf2 regulators
US20200071310A1 (en) 2016-12-12 2020-03-05 Glaxosmithkline Intellectual Property Development Limited N-aryl pyrazoles as nrf2 regulators
JP2020500919A (ja) 2016-12-12 2020-01-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Nrf2レギュレーターとしての3−カルボン酸ピロール
WO2018109647A1 (en) 2016-12-14 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Bisaryl amides as nrf2 regulators
US20220002272A1 (en) 2016-12-14 2022-01-06 Glaxosmithkline Intellectual Property Development Limited Bisaryl lactams as nrf2 activators
EP3555078B1 (en) 2016-12-14 2024-03-27 GlaxoSmithKline Intellectual Property Development Limited Bisaryl heterocycles as nrf2 activators
RU2019121673A (ru) 2016-12-15 2021-01-15 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Активаторы nrf2
WO2018109649A1 (en) 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Ether linked triazoles as nrf2 regulators
AR110590A1 (es) 2016-12-27 2019-04-10 Biogen Ma Inc Activador de nrf2
US20190389836A1 (en) 2017-01-30 2019-12-26 Biogen Ma Inc. Nrf2 activator
WO2018140738A1 (en) 2017-01-30 2018-08-02 Biogen Ma Inc. Nrf 2 activator
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物

Also Published As

Publication number Publication date
JP2022510736A (ja) 2022-01-27
US11518763B2 (en) 2022-12-06
BR112021010704A2 (pt) 2021-08-24
UA127872C2 (uk) 2024-01-31
EP3890738A4 (en) 2022-08-17
AR117251A1 (es) 2021-07-21
AU2019391942A1 (en) 2021-06-03
CL2021001451A1 (es) 2021-12-24
TW202039494A (zh) 2020-11-01
AU2019391942B2 (en) 2024-03-21
KR20210099622A (ko) 2021-08-12
SG11202105125XA (en) 2021-06-29
PH12021551262A1 (en) 2021-10-25
CA3121952A1 (en) 2020-06-11
US20220119391A1 (en) 2022-04-21
CO2021007304A2 (es) 2021-06-21
WO2020116660A1 (en) 2020-06-11
EP3890738A1 (en) 2021-10-13
TWI820266B (zh) 2023-11-01
CN113164468A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
PH12021551262A1 (en) Macrocyclic compound and use thereof
MX365986B (es) Derivativos de piperidina fusionados con espiro para usarse como inhibidores del canal de potasio medular externo renal.
MD20160069A2 (ro) Inhibitor al kinazei inductoare de apoptoză
NZ712745A (en) Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis
PH12018500261A1 (en) Azole benzene derivative
MX2010003603A (es) Metodo para el tratamiento de enfermedades de riñon poliquisticas con derivados de ceramida.
WO2014126944A3 (en) Inhibitors of the renal outer medullary potassium channel
PE20211595A1 (es) Compuestos de 2,6-diaminopiridina
GEP20207095B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
WO2015095097A3 (en) Inhibitors of the renal outer medullary potassium channel
MX361925B (es) Medicamento inhalable que comprende tiotropio.
WO2016057658A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
CL2021003342A1 (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa.
MX2022004744A (es) Composiciones que comprenden 2'-fucosil-lactosa para prevenir el asma.
NZ590454A (en) Glucocorticoids attached to nitrate esters via an aromatic linker in position 21 and their use in ophthalmology
MY183186A (en) Phenyl derivative
SA515360085B1 (ar) مشتق ودواء بيريدين
PH12015502264A1 (en) Pyrazole derivative
Althaqfi et al. Results of brachytherapy in anal cancer from a cohort of 173 patients treated at the same institution over a 20 year period
Grubnik et al. Complex treatment of patients with cirrhosis complicated by variceal bleeding
WO2014176510A3 (en) N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8-(dimethylamino) naphthalen-1(4h)-ylidene)-n-methylmethanaminium, derivatives, and their use in treating cancer
UA102971U (ru) Способ коррекции метаболических нарушений в легких крыс при ожоговой болезни
Dean et al. A52 PRECLINICAL TRIALS IN PULMONARY HYPERTENSION MODELS: NOVEL TARGETS AND DELIVERY: Effect Of Metformin On Pulmonary Hypertension In The Sugen/hypoxic Rat Model: Possible Role For Aromatase
Mittal Dopamine/norepinephrine
Terasaki et al. B63 MOLECULAR INSIGHTS INTO LUNG CANCER II: Hydrogen-Supplemented Drinking Water Protects Against Naphthalene-Gefitinib Induced Lung Injury From Inflammation-Associated Oxidative Stress